BNTX · BioNTech SE
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BNTX
this stock
BioNTech SE
|
$29.28B | +18.5% | — | — | 1.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.30B | +7.3% | +20.8% | 20.5 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +20.2% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BNTX | +23.2% | +23.9% | +12.0% | +24.6% | +18.5% |
| SPY | -1.2% | +3.3% | +12.2% | +2.2% | +12.0% |
| vs SPY | +24.4% | +20.6% | -0.3% | +22.4% | +6.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.